Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.

CONCLUSIONS: Esmirtazapine reduced the frequency and severity of moderate to severe VMS associated with menopause and was generally well tolerated in the study population.
PMID: 30712391 [PubMed - as supplied by publisher]

Source: Climacteric - February 4, 2019 Category: Geriatrics Authors: Birkhaeuser M, Bitzer J, Braat S, Ramos Y Tags: Climacteric Source Type: research